Mandate

Vinge advises iBinder in connection with the acquisition of SundaHus i Linköping Aktiebolag

Vinge advises iBinder in connection with the acquisition of SundaHus i Linköping Aktiebolag ("SundaHus"). Through the acquisition of SundaHus, iBinder strengthens its position as a leading Nordic digital platform for efficient information management and collaboration in the construction and real estate industry.

Every year, a total of 3,000 customers use the companies' solutions to efficiently run and quality assure projects. In total, the companies have managed over 70,000 projects in 8 countries. SundaHus provides a digital information system to property owners to facilitate and enable conscious material choices within health and sustainability.

Vinge’s team consisted of, among others, Jonas Bergström, Johanna Wiberg and Olivia Belding (M&A), Axel Lennartsson and Sofia Bergenstråhle (IP), Karl-Gustaw Tobola and Lisa Hörnqvist (Corporate Commercial), Karolina Fuhrman and Mathilda Persson (IT), Daniel Melander Björner (Employment), Victor Ericsson (Tax) as well as Karl-Hugo Engdahl (GDPR).

 

Related

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025